ABSTRACT
El modelo clásico de la hemocromatosis neonatal contemplaba la analogía con la hemocromatosis hereditaria. El tratamiento médico se basaba en un cóctel quelante/antioxidante. La hipótesis actual de un origen aloinmunitario del proceso, en el que la madre gestante monta una respuesta destructiva de tipo IgG contra los hepatocitos fetales, ha ofrecido una mejor explicación fsiopatológica y permite enfocar el tratamiento en el aspecto inmunológico con excelentes resultados, incluso previniendo la enfermedad en embarazos posteriores. Este cambio de paradigma repercute profundamente en el diagnóstico, pronóstico y tratamiento de la enfermedad, que debería denominarse "hepatitis fetal aloinmunitaria".
The classical model of neonatal hemochromatosis was based on the analogy with hereditary hemochromatosis. Medical treatment consisted on the antioxidant-chelator cocktail. The new hypothesis of an alloimmune origin of the process by which the pregnant woman mounts an IgG-based destructive response against fetal hepatocytes offers a pathogenic explanation, allowing treatment to be focused on the immunological aspects, with excellent results, and opens the possibility of preventive treatment in future pregnancies. This new paradigm produces a deep impact in diagnosis, prognosis and treatment of the disease, that should be called "fetal alloimmune hepatitis".
Subject(s)
Humans , Infant, Newborn , Hemochromatosis/immunology , Fetal Diseases/immunology , Hemochromatosis/diagnosis , Hemochromatosis/drug therapy , Hemochromatosis/etiologyABSTRACT
A hemocromatose caracteriza-se pelo acúmulo excessivo de ferro no organismo, que é depositado redominantemente no fígado, e resulta ou de um defeito genético determinando uma absorção excessiva de ferro ou da administração parenteral deste íon. O ferro em excesso determina alterações celulares através da peroxidação lipídica, estímulo da deposição de colágeno e interação com o oxigênio reativo e DNA. Os autores relatam um caso de hemocromatose em paciente portador de cirrose hepática associada ao desenvolvimento de hepatocarcinoma, hemangioma hepático, adenocarcinoma prostático e carcinoma renal, e apresentam uma discussão geral deste processo, frequentemente associado ao desenvolvimento de neoplasias.
Hemochromatosis is characterized by excessive accumulation of iron in the body, which is deposited primarily in the liver. It results either from a genetic defect determining an excessive absorption of iron or from parenteral administration of this ion. The excess iron determines cellular changes through lipid peroxidation, stimulation of collagen deposition, and interaction with reactive oxygen and DNA. The authors report a case of hemochromatosis in a patient with liver cirrhosis associated with development of hepatocellular carcinoma, hepatic hemangioma, prostate adenocarcinoma and renal cell carcinoma, and provide a general discussion of this process often associated with the development of neoplasias.
Subject(s)
Humans , Male , Middle Aged , Hemochromatosis/genetics , Hemochromatosis/drug therapy , Liver Neoplasms/complications , Kidney Neoplasms/complications , Adenocarcinoma/complications , Carcinoma, Hepatocellular/complications , Carcinoma, Renal Cell/complications , Liver Cirrhosis/complicationsABSTRACT
La hemocromatosis neonatal es una enfermedad hepática muy severa del recién nacido y se asocia a una alta mortalidad. Se cree que su etiología es de tipo aloinmune, debido a la presencia de un anticuerpo materno hasta ahora desconocido que interfiere con el metabolismo férrico del feto, llegando a producir gran morb i mortal ¡dad. Basándonos en esta teoría, el tratamiento materno con inmunoglobulinas intravenosas en gestaciones sucesivas podría prevenir el desarrollo de un nuevo cuadro de hemocromatosis neonatal. Se describe el caso de una gestante con un hijo anterior diagnosticado y fallecido neonatalmente por hemocromatosis, a la que en el embarazo actual se le trató con inmunoglobulinas intravenosas consiguiendo un hijo sano y vivo. Es el primer caso descrito en España y demuestra el éxito de esta terapia, tal como describe la literatura.
Neonatal hemochromatosis is a severe neonatal liver disease with a high mortality and recurrence rate. It is supposed to be a gestational alloimmune disease because of the existence of maternal antibodies against fetal hepatic metabolism. On the basis of this hypothesis, the administration of intravenous immunoglobulin has been reported as a successful treatment during the following pregnancy. We describe the first case of this treatment in Spain which confirms the data available in the literature.
Subject(s)
Humans , Female , Pregnancy , Infant, Newborn , Hemochromatosis/drug therapy , Immunoglobulins, Intravenous/therapeutic use , Hemochromatosis/pathology , Liver/pathology , Treatment OutcomeABSTRACT
Drug-induced liver injury is a common side-effect of many medicines. It is particularly problem when the original condition under treatment is already causing liver damage. This report describes the hepatotoxicity induced by Deferasirox in a patient with haemochromatosis with a discussion of possible pathogenetic mechanisum
Subject(s)
Humans , Female , Chemical and Drug Induced Liver Injury/etiology , Hemochromatosis/drug therapy , Triazoles/adverse effects , Iron Chelating Agents/adverse effects , Chelation Therapy , Treatment OutcomeABSTRACT
Hemochromatosis, especially with cardiac and liver problem, is rare in Iran. We report a young female with pulmonary hypertension and abnormal liver function tests due to non HFE- related hemochromatosis
Subject(s)
Humans , Female , Hemochromatosis/complications , Hemochromatosis/drug therapy , Hemochromatosis/genetics , Hypertension, Pulmonary/etiology , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/therapy , Liver Function Tests , Histocompatibility Antigens Class I , /etiology , Deferoxamine , Contraceptives, Oral , Ferritins , Menorrhagia/etiology , Menorrhagia/therapy , Dyspnea/etiologySubject(s)
Humans , Male , Hemochromatosis/drug therapy , Infant, Newborn , Infant, Newborn, Diseases , Antioxidants , DeferoxamineABSTRACT
Twenty-four patients with beta thalassaemia major, aged 8-22 years (mean 15.3 +/- 8.1) were given 1-2, dimethyl-3-hydroxypyrid-4-one (L1) orally for a period of three months. The drug was given in the dose of 25 mg/Kg/day for the first week and gradually increased to 100 mg/Kg/day which was continued until 3 months. The mean urinary iron excretion was 5.73 +/- 3.648 mg/day on 25 mg/Kg/day of L1; 15.2 +/- 11.225 mg/day on 50 mg/Kg/day; 24.2 +/- 12.69 mg/day on 75 mg/Kg/day and 36.3 +/- 19.4 mg/day on 100 mg/Kg/day of L1. Serum ferritin estimated by ELISA before and 3 months after L1 therapy in 21 patients showed significant drop in levels, the mean drop being 964.3 +/- 844.4 (P less than 0.001). The only side-effects noted were transient gastrointestinal symptoms in 5 patients and skeletomuscular pain in 3 patients. Both these groups of symptoms were of transient nature. The efficacy of L1 appears to be excellent and equivalent to the standard iron chelation therapy available at present i.e. desferrioxamine. It appears to be free of major toxicity. L1 is also a specific chelator for iron as it does not deplete trace metals. L1 appears to be a cheap and effective oral alternative to desferrioxamine for treating iron overloading.